What is Quotient Switzerland?
Quotient Switzerland is a commercial-stage diagnostics company with over three decades of experience, dedicated to transforming diagnostic practices. Its proprietary MosaiQ technology represents a groundbreaking, fully automated multiplex microarray platform capable of performing multiple tests across various modalities. This innovative solution is engineered to enhance laboratory efficiencies, improve clinical outcomes, and deliver substantial operational cost savings. The company has also demonstrated agility by developing the MosaiQ COVID-19 Antibody Microarray, which has achieved CE marking and U.S. FDA Emergency Use Authorization, highlighting its responsiveness to global health needs. Quotient operates globally with facilities in Eysins, Switzerland, Edinburgh, Scotland, and Newtown, Pennsylvania.
How much funding has Quotient Switzerland raised?
Quotient Switzerland has raised a total of $219M across 3 funding rounds:
Stock Offering
$40M
Debt
$84M
Stock Offering
$95M
Stock Issuance/Offering (2014): $40M, investors not publicly disclosed
Debt (2016): $84M led by Morgan Stanley & Co. LLC
Stock Issuance/Offering (2021): $95M, investors not publicly disclosed
What's next for Quotient Switzerland?
With a history of substantial enterprise-level funding, Quotient Switzerland is strategically positioned for continued growth and innovation in the diagnostics sector. The recent major strategic investment signals strong confidence from backers in the company's long-term vision and the disruptive potential of the MosaiQ platform. This capital is expected to fuel further development, market expansion, and the scaling of its diagnostic solutions, particularly in addressing critical areas like infectious disease testing. The company's focus on increasing laboratory efficiencies and reducing costs aligns with current healthcare system demands, suggesting a trajectory towards broader adoption and market leadership.
See full Quotient Switzerland company page
